Close

Five Prime Therapeutics (FPRX) Submits Investigational NDA for Novel B7-H4 Antibody FPA150

January 3, 2018 4:09 PM EST Send to a Friend
Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, today announced the December ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login